NorthX Biologics

NorthX Biologics is a Swedish pharmaceutical company with a focus on process development and large-scale production of advanced biological drugs

An innovation hub for collaboration with innovative biotech companies and research institutes.

NorthX Biologics is a Swedish pharmaceutical company focusing on process development and large scale manufacturing of advanced biological therapies for innovative biotech companies and research institutes.

The new company is owned by Flerie Invest. The previous owner of the Matfors site was Cobra Biologics, a subsidiary of the American pharmaceutical company Charles River Laboratories.

Flerie Invest will develop and expand the operations to create a state of the art production hub for advanced therapies and vaccines, based on DNA, RNA, proteins, and cells.

NorthX Biologics will collaborate with innovative biotech companies in Sweden, the Nordics and internationally.

Today, the company has a facility in Matfors specialised in DNA- and protein manufacturing, with 128 highly qualified staff.

The Swedish Government have given Vinnova (Sweden's innovation agency) the mandate to support the establishment of an innovation hub alongside NorthX Biologics in Matfors. This will lead to various forms of collaboration between innovative biotech companies and other actors in Sweden, the Nordics and internationally.

A unique site with highly qualified staff

The 7000 square metre site in Matfors supports the production of proteins, DNA-based and microbial therapeutics.

The facility is certified according to the internationally recognised quality standard, GMP (Good Manufacturing Practice).

Today there are 128 experienced and highly qualified employees, including researchers with PhDs, biochemists, biotechnology engineers, and development specialists.

The site was first established in 1963 as a part of Sundsvall Pharmacy, and has since then expanded significantly.

NorthX Biologics have the ability to become a global leader within ATMP production.

We see enormous potential to further develop the factory in Matfors, and will invest in an expansion. Flerie Invest will finance this expansion with support from Vinnova.

This page will be kept updated - stay tuned for further news about the expansion

Creating value for society: Improving and saving lives

Through the expansion of the Matfors site, Life Science SMEs (small and medium-sized enterprises) will have access to process development and the production capacity to manufacture advanced therapeutics and vaccines.

By sharing resources, research groups and innovative small and medium sized pharmaceutical companies can have access to advanced, large scale infrastructure at a competitive price, enabling large scale international commercialisation.

Today, many Swedish and European biotech companies choose to have their production outside of Sweden. As a result of the new innovation hub in Matfors, we will be able to attract and support the manufacture and development of new therapeutics in Sweden and Europe.

“Through the investment in the innovation hub in Matfors, we will be able to maintain the production and development of new drugs in Sweden, which is an important piece of the puzzle for building Sweden's position as a leading nation in life science. The innovation hub for advanced development and production will complement Testa Center in Uppsala, which supports companies and researchers in the early stages of development of new biological drugs” says Jenni Nordborg, national coordinator for Life science and head of the government's Life science office.

“Testa Center in Uppsala, with support from Vinnova, has helped many innovative companies to develop novel pharmaceutical processes that could be applied at larger scale at NorthX Biologics” says Lotta Ljungqvist, CEO of Testa Center.

Next generation biopharmaceuticals will result in a new revolution that will help us face some of the biggest health challenges of our time, such as cancer, diabetes, obesity, and future pandemics. The new therapeutic modalities will save and improve lives.

Reserve capacity for vaccine production

The infrastructure in Matfors will also serve as reserve capacity for vaccine production. This will allow Sweden and the Nordics to become self-sufficient in future pandemics.

Our owners

Flerie Invest is a biotech and pharma investor with offices in Stockholm and London. The portfolio consists of more than 16 companies in Sweden, UK, US, the Netherlands, Iceland and Israel. The companies are active in a wide range of areas, including gene therapy and vaccines. The company was founded in 2010 by Thomas Eldered, who together with Lars Backsell started Recipharm and built it to be one of the top five CDMOs globally.

Flerie Invest is a biotech and pharma investor with offices in Stockholm and London. The portfolio consists of more than 16 companies in Sweden, UK, US, the Netherlands, Iceland and Israel. The companies are active in a wide range of areas, including gene therapy and vaccines. The company was founded in 2010 by Thomas Eldered, who together with Lars Backsell started Recipharm and built it to be one of the top five CDMOs globally.